Terms ending in 2028
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,343,933 | Variants Derived from Actriib and Uses Therefor In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 9,399,669 | Variants Derived from Actriib In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,259,861 | Variants Derived from Actriib and Uses Therefor In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 7,842,663 | Variants Derived from Actriib and Uses Therefor In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,093,707 | Antagonists of Activin-Actriia and Uses for Increasing Red Blood Cell Levels In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 8,367,611 | Activin-Actriia Antagonists for Inhibiting Germ Cell Maturation In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 9,353,356 | Activin-Actriia Antagonists for Treating a Follicle-Stimulating Hormone-Secreting Pituitary Tumor In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 8,455,428 | ALK1 Receptor and Ligand Antagonists and Uses Thereof In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 7,960,343 | Activin-Actriia Antagonists and Uses for Decreasing or Inhibiting FSH Secretion In force · High confidence | Acceleron Pharma Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.